Genmab A (GMAB) Change in Accured Expenses (2023 - 2026)

Genmab A's Change in Accured Expenses history runs 4 years deep, the most recent figure standing at -$261.0 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 467.39% year-over-year to -$261.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$155.0 million (down 158.27% YoY) and the FY2024 annual result came in at $122.0 million, up 35.56% from the prior year.
• Change in Accured Expenses was -$261.0 million for Q1 2026 at Genmab A, down from $101.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $122.0 million in Q4 2024 and bottomed at -$261.0 million in Q1 2026.
• A 4-year average of $30.7 million and a median of $81.0 million in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses soared 35.56% — and 2026, when it plunged 467.39%.
• Genmab A's Change in Accured Expenses stood at $90.0 million in 2023, then surged by 35.56% to $122.0 million in 2024, then decreased by 17.21% to $101.0 million in 2025, then sank by 358.42% to -$261.0 million in 2026.
• Business Quant data shows GMAB's Change in Accured Expenses at -$261.0 million in Q1 2026, $101.0 million in Q3 2025, and $51.0 million in Q2 2025.